BioSpace News Archive

Corbus Pharmaceuticals Holdings, Inc. announced the closing of its public offering of 4,973,750 shares of its common stock, including 648,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

Fate Therapeutics, Inc. announced that on February 1, 2024 the Company granted restricted stock units representing 32,600 shares of its common stock to two newly-hired non-executive employees.

Axogen, Inc. announced making Inducement Grants Under NASDAQ Listing Rule 5635 in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales.

Tempest Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 45,500 shares of its common stock under the Company’s 2023 Inducement Plan.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, announced the grant of inducement awards to five new employees.

Synlogic, Inc. (Nasdaq: SYBX) announced today the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clinical proof of mechanism in healthy volunteers through the successful lowering of methionine (Met), a precursor to homocysteine, in a dietary model of classical homocystinuria (HCU).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Syndax Pharmaceuticals announced that on February 1, 2024 the Company granted inducement awards to purchase up to 127,300 shares of common stock to eight new employees under the Company’s 2023 Inducement Plan.

Olema Pharmaceuticals, Inc. announced that the Company granted stock options to four new employees to purchase an aggregate of 33,600 shares of the Company’s common stock, effective as of February 1, 2024.

Tyra Biosciences, Inc. announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the PIPE) for gross proceeds of approximately $200 million.